American Society of Hematology

AML Matters Program

A Multidisciplinary Approach to Testing and Diagnosis, Evaluation of Risk, and Personalized Treatment Selection

AML Matters is an education program designed to improve the diagnosis and treatment of acute myeloid leukemia (AML). The program is being hosted by ASH, American Society for Clinical Pathology, National Marrow Donor Program, Oncology Nursing Society, and The France Foundation.

AML was diagnosed in approximately 20,000 people in the United States in 2016, and of those patients more than half will die from this disease. Recently, there have been significant advances in the diagnosis and management of AML, which warrant ongoing education for the interdisciplinary care team involved in the management of patients with AML.

This educational program was designed to provide guidance to the interdisciplinary AML care team on the optimal diagnosis and classification of AML, risk stratification, and individualized treatment selection, as well as assessment of treatment responses, monitoring for and mitigation of adverse events, and patient education regarding prognosis and treatment choices.

In 2017, program participants attended one of four summits held in North America and actively engaged in multidisciplinary, interactive small-group activities focused on the following topics:

  • a case-based tumor board
  • diagnosing AML
  • treatment decision-making
  • MRD/CR1 and the role of transplants
  • relapsed refractory disease

The target audience for this program included hematology/oncology physicians, advance practice professionals, nurses, pathologists, hematopathologists, HCT clinicians, and other health care professionals.

back to top